oral lung penetrant RSV fusion inhibitor

Ph. II candidate (50 mg BID) for RSV infect.

opt. from literature starting point

J. Med. Chem., Mar. 17, 2021

Reviral Ltd, Hertfordshire, UK

The Reviral respiratory syncytial virus (RSV) fusion inhibitor (sisunatovir) is an oral Ph. II clinical candidate that demonstrated reduction in viral load and total symptom score in RSV-infected patients…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks